Companies may potentially accelerate the approval of generic drugs by avoiding deficiencies in ANDA submissions.
Susan Rosencrance
Advertisement
Susan Rosencrance, PhD is with the Center for Drug Evaluation and Research, FDA
Articles by Susan Rosencrance
An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Advertisement
Latest Updated Articles
Common Deficiencies in ANDAs for Dermatologic Drug ProductsSeptember 2nd 2016
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
5